Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

Systematic Targeting Of MicroPlastics (STOMP)

Active
ARPA-H-SOL-26-152Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The solicitation ARPA-H-SOL-26-152 issued by the Advanced Research Projects Agency for Health (ARPA-H) under the Department of Health and Human Services is an Innovative Solutions Opening (ISO) aimed at advancing the Systematic Targeting Of MicroPlastics (STOMP) program. This solicitation, posted on May 6, 2026, and amended twice, anticipates multiple Other Transaction (OT) Agreements focused on milestone-based fixed-price efforts. The work spans six fiscal years from December 2025 through November 2031, emphasizing innovative research to develop technologies related to microplastic detection and mitigation, with performance guided by a detailed Task Description Document (TDD). The evaluation prioritizes technical and scientific merit foremost, followed by the proposer’s capabilities and a reasonableness assessment of cost proposals, employing a trade-off award process rather than lowest price. Key personnel are subject to stringent research security requirements, including foreign affiliation disclosures and annual certifications against participation in foreign talent recruitment programs. Organizational conflict of interest (OCI) provisions exclude entities providing recent ARPA-H support, and federal research entities face restrictions. Deliverables are milestone-driven, with acceptance and payment contingent upon satisfactory completion confirmed by ARPA-H representatives. The solicitation mandates annual data sharing with other awardees and enforces strict IP and confidentiality controls. Submission requires multiple volumes covering technical, cost, administrative, and policy compliance elements, with specific formatting and portal registration procedures. While no standardized FAR clauses are included, the agreement relies on internal provisions and ARPA-H’s unique OT framework to promote cutting-edge research through flexible, performance-based agreements.

General Info

ARPA-H seeks milestone-based OT agreements for innovative microplastic detection and mitigation technologies.

Agency

Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Washington, DC, USA

Set-Aside

NONE

Documents

(7)

ARPA-H STOMP ISO Solicitation ARPA-H-SOL-26-152 Amendment 2

PDFamendment

STOMP_ISO_Volume+II_ARPA-H+COST+PROPOSAL+SPREADSHEET+%28Other+Transaction%29.xlsx

XLSX

STOMP_ISO_ARPA-H-SOL-26-152_Amendment+1.pdf

PDF

STOMP_ISO_Volume+I_ARPA-H+Preliminary+Task+Description+Document+%28TDD%29.docx

DOCX

ARPA-H STOMP Innovative Solutions Opening ISO ARPA-H-SOL-26-152

PDFiso

STOMP+ISO_ARPA-H-SOL-26-152+Amendment+3.pdf

PDF

STOMP_ISO_Volume+III_ARPA-H+Sample+OT+Agreement.docx

DOCX

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

3 updates
PhaseSolicitation
Amendment 2

Contract was updated

Posted

Solicitation

Amendment 0

Contract was updated

Amendment 3

Contract was updated

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
Contacts1 person available
OfficeWashington, DC, 20005, USA
Organization / Agency
Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
Office AddressWashington, DC, 20005, USA
Contacts
The STOMP Team

Full Description

Show more

June 2, 2026 - Amendment 3 to STOMP ISO ARPA-H-SOL-26-152. This amendment incorporates the following changes:


1. Figure 8: TA2.1 metrics and Section 2.5 Microplastics Samples has been updated. 


All other terms and conditions remain unchanged. 


________________________________________________________________________


May 6, 2026 - Amendment 2 to STOMP ISO ARPA-H-SOL-26-152. This amendment incorporates the following changes:


1. Corrects a typo under Figure 4: TA1.2 metrics, from 50 µm to 50 nm. 


2. Section B. Cost and Pricing Data Support under page 46 has been revised. The requirements that have been removed are only necessary if proposers are selected for negotiations.  


All other terms and conditions remain unchanged. 


____________________________________________________________


April 20, 2026 - Amendment 1 to STOMP ISO ARPA-H-SOL-26-152. This amendment corrects the Figure number on Page 11 and incorporates Figure 6 on Page 15.


_____________________________________________________________________


All questions submitted to the ISO will be compiled and addressed. Responses will be posted to the STOMP Frequently Asked Questions (FAQ) page. Potential proposers are encouraged to monitor the FAQ page regularly for the latest information and updates: https://arpa-h.gov/explore-funding/programs/stomp/faqs


_____________________________________________________________________


The Advanced Research Projects Agency for Health (ARPA-H) is posting this Innovative Solutions Opening (ISO) in support of the Systematic Targeting Of MicroPlastics (STOMP) Program. ARPA-H anticipates multiple Other Transaction (OT) Agreements will result from this announcement. Interested parties are invited to review the STOMP_ISO_ARPA-H-SOL-26-152 and assciated attachments.


Additionally, proposers are encouraged to review the separate Special Notice, ARPA-H-SN-26-150, for information regarding the STOMP Proposers’ Day. Special Notice (SN), ARPA-H-SN-26-150, is an independent announcement and is not attached to this ISO announcement.

Similar Contracts

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
View Details
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day
View Details